Faculty

Statement of Need

Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting over 1.3 million Americans and approximately 1% of the global population.¹ Many treatment options are available to treat RA, and these agents may be used as monotherapy, as sequential treatment strategies, or as combination treatment. To successfully treat patients with RA, clinicians must be aware of the various treatment strategies outlined in the ACR guidelines and clinical evidence that supports these treat-to-target approaches. The management of RA is complex and requires the involvement of the entire treatment team—that includes the patient—in order to maximize the benefits of existing treatment approaches, incorporate new treatments when appropriate, and ensure the health care needs of all patients with RA are met.

This live, interactive webcast features a panel discussion moderated by Leonard Calabrese, DO with audio input from patients with RA, video interviews from RA team care members at the Cleveland Clinic, and a live Q&A.

Reference:
Rheumatoid Arthritis Support Network. Rheumatoid arthritis facts and figures. Rheumatoid Arthritis Support Network Website. https://www.rheumatoidarthritis.org/ra/facts-and-statistics/.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Align treatment decisions with ACR recommendations which support a treat-to-target approach in the care of patients with RA.
• Critically appraise DMARD monotherapy treatment options, including JAK-inhibitors in the care of patients with moderate-to-severe RA.
• Integrate one best practice that can be utilized by the multidisciplinary care team to monitor for signs and symptoms of methotrexate intolerance and medication nonadherence.

The following learning objectives pertain only to those requesting CNE or CPE credit:

• Describe treatment decisions that align with ACR recommendations which support a treat-to-target approach in the care of patients with RA.
• Critically appraise DMARD monotherapy treatment options, including JAK-inhibitors in the care of patients with moderate-to-severe RA.
• Identify best practices that can be utilized by the multidisciplinary care team to monitor for signs and symptoms of methotrexate intolerance and medication nonadherence.

Financial Support

Supported by an educational grant from Pfizer Inc.

Target Audience

Rheumatologists, PAs, NPs, nurses, pharmacists, and other healthcare providers who treat patients with rheumatoid arthritis.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours

Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology.  Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.

Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit^TMthrough the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)^TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Live: 0376-0000-18-003-L01-P
Enduring: 0376-0000-18-003-H01-P

Type: Knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity
Enduring material

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit^TM from organizations accredited by the Accreditation Council for Continuing Medical Education.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST26326 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Calabrese reports that he is a consultant for AbbVie Inc.; Centecor Biopharmaceutical; Crescendo Bioscience, Inc.; GlaxoSmithKline; Horizon Pharma; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; and UCB, Inc.

Dr. Stanley B. Cohen has no disclosures to report.

Ms. Eileen J. Lydon has no disclosures to report.

Dr. Rochelle Rosian has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.